TABLE 2.
Clinical and demographic information of participants who donated cerebrospinal fluid samples.
| NMOSD (n = 18) | NMOSD | OND (n = 17) | p | ||
|---|---|---|---|---|---|
| Relapse (n = 12) | Remission (n = 6) | ||||
| Gender (F/M) | 16/2 | 12/0 | 4/2 | 9/8 | 0.009 a |
| Age, mean ± SD, years | 40.1 ± 13.3 | 34.6 ± 9.6 | 51.2 ± 13.2 | 43.8 ± 10.7 | 0.008 b |
| EDSS at measurement, median (range) | 3.8 (1.0–8.0) | 3.8 (2.0–8.0) | 3.5 (1.0–5.5) | — | 0.421 b |
| Medication within last 6 months | |||||
| Glucocorticoids | 14/18 | 10/12 | 4/6 | — | |
| Gamma globulin | 4/18 | 2/12 | 2/6 | — | |
| Plasma exchange | 1/18 | 1/12 | 0/6 | — | |
| Disease-modifying therapy | 9/18 | 5/12 | 4/6 | — | |
| Neurotrophic drugs | 13/18 | 8/12 | 5/6 | — | |
| Traditional Chinese Medicine | 1/18 | 0/12 | 1/6 | — | |
Continuous variables are shown as the means ± SD, and noncontinuous variables are shown as the median (range). Count data are detected by the chi-squared test.
NMOSD, neuromyelitis optica spectrum disorders; OND, other neurological diseases; EDSS, expanded disability status scale. Disease-modifying therapies include mycophenolate mofetil, rituximab, cyclophosphamide, and azathioprine.
a
NMOSD-relapse vs. OND.
b
NMOSD-relapse vs. NMOSD-remission.